Results 131 to 140 of about 160,640 (261)
Which Firms Have a Soft Loan ? Managers' Believes in a Cross-Country Survey in Transition Economies [PDF]
This paper is an empirical work grounded in the soft budget constraint literature. A loan is soft when a bank cannot commit to hold an enterprise to a fixed initial budget and/or the timing of repayment.
Bignebat, C., Gouret, F.
core
In this Phase III study, secukinumab demonstrated sustained efficacy and a favourable safety profile in paediatric patients with chronic severe plaque psoriasis over a treatment period of 236 weeks. Abstract Background Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population.
Andrzej Kaszuba +11 more
wiley +1 more source
Left-Sided Poland Syndrome With No Hand Anomalies: A Case Report. [PDF]
Sami H +4 more
europepmc +1 more source
Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis +54 more
wiley +1 more source
Moebius- Poland Syndrome: A case report
Moebius syndrome (OMIM 157900) is a congenital disorder related to paralysis of the VI and VII cranial nerves. Clinical findings include mainly facial nerve palsy and strabismus.
Mostapha Ahmad +5 more
doaj
Management of Axillary Contracture in Poland Syndrome: Differentiating Fibrous Band and Skin for Optimal Release. [PDF]
Matsuura R +4 more
europepmc +1 more source
Poland’s syndrome (PS) is a rarely encountered congenital disorder that is characterised withabsence of pectoralis major muscle. However, hand and other organ anomalies may accompanythe syndrome. It is usually right sided. We report the left sided two PS cases.
BULUT, İsmet +2 more
openaire +2 more sources
Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat +22 more
wiley +1 more source

